THDG3
/ Deck Therap
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 16, 2024
Developing Novel Drug Candidates In An Ovine Model Of Neonatal Hypoxic-Ischemic Encephalopathy - An Overview Of Neurobehavioral Outcomes
(PAS 2024)
- "We studied lambs that were treated with azithromycin, low- and high-dose caffeine, THDG3, clemastine and combined azithromycin and caffeine. Overall, perinatal caffeine administration demonstrated greatest benefit: ability to feed on Day 2 (p=0.0256) and increased activity on Day 1 (p=0.0034) and 2 (p=0.0391). A higher dose, as well as combined postnatal caffeine and azithromycin administration, along with THDG3, demonstrated significant toxicity and were discontinued early."
CNS Disorders
1 to 1
Of
1
Go to page
1